Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination.
Quantifying the early stages of remyelination following cuprizone-induced demyelination.
Sex differences in autoimmune diseases.
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Effects of dimethyl fumarate on neuroprotection and immunomodulation.
Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis.
Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS)
TECFIDERA prescribing information
Optical coherence tomography reflects brain atrophy in MS: A four year study.
Oral BG-12 (dimethyl fumarate) significantly reduced multiple sclerosis (MS) relapses and disability progression in DEFINE Phase 3 clinical trial
Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis.
Spotlight on teriflunomide.
In vitro and in vivo pharmacological models to assess demyelination and remyelination.
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)
Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study.
MRI identification of the rostral-caudal pattern of pathology within the corpus callosum in the cuprizone mouse model.
New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response.
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
The neuroendocrine axis in patients with multiple sclerosis.
Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.
Extracellular Cues Influencing Oligodendrocyte Differentiation and (Re)myelination.
MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.
Origin, fate and dynamics of macrophages at central nervous system interfaces.
Gene expression in brain during cuprizone-induced demyelination and remyelination.

Pages